Myositis and Autoimmune ILD
|
|
- Vernon Snow
- 5 years ago
- Views:
Transcription
1 Myositis and Autoimmune ILD 2018 AURA Annual Meeting Sedona, Arizona June 2, 2018 Chester V. Oddis, MD Director, Myositis Center University of Pittsburgh
2 Disclosures Genentech: Clinical trial support Idera: Clinical trial participant Mallinckrodt: Clinical trial support; Advisory Board
3 Lecture Objectives Discuss selected clinical features of myositis classification. Discuss spectrum of autoantibodies seen in patients with myositis and their clinical associations Discuss selected treatment aspects of myositis and autoimmune ILD
4 Classification of Myositis Adult polymyositis Adult dermatomyositis Juvenile myositis (DM >> PM) Malignancy-associated myositis Myositis in overlap with another AI disease Inclusion body myositis (IBM)
5 IIM: Diagnostic Criteria Bohan and Peter (1975) Symmetric proximal muscle weakness Elevation of serum muscle enzymes: CK, aldolase, AST, ALT, LDH Myopathic electromyographic abnormalities: sharp waves, fibrillations, polyphasic motor units, high frequency repetitive discharges Characteristic muscle pathology: myofiber degeneration/regeneration, MNC infiltrates, perifascicular atrophy
6 Rashes of Dermatomyositis Rashes of Dermatomyositis
7 Cuticular Thickening and Periungual Erythema Nail fold capillary abnormality
8 Classification of Myositis Adult polymyositis Adult dermatomyositis Juvenile myositis (DM >> PM) Malignancy-associated myositis Myositis in overlap with another AI disease Inclusion body myositis (IBM)
9 Classification of Myositis Adult polymyositis Adult dermatomyositis Juvenile myositis (DM >> PM) Malignancy-associated myositis Myositis in overlap with another AI disease Inclusion body myositis (IBM)
10 Polymyositis Mimics Endocrine myopathies hyper/hypothyroid Drug or toxic myopathies Metabolic myopathies Mitochondrial myopathies Muscular dystrophies Infectious myositis Neuropathies/neurologic syndromes Paraneoplastic syndromes Other connective tissue disorders Miscellaneous amyloid, sarcoid
11 Muscle Biopsy is a Must in Polymyositis (unlike classic DM)
12 Classification of Myositis Adult polymyositis Adult dermatomyositis Juvenile myositis (DM >> PM) Malignancy-associated myositis Myositis in overlap with another AI disease Inclusion body myositis (IBM) Necrotizing myopathy (NM) What we called PM before, in some cases, is now called NM
13 Neurology, 2003
14 Classification of Myositis Adult polymyositis Adult dermatomyositis Juvenile myositis (DM >> PM) Malignancy-associated myositis Myositis in overlap with another AI disease Inclusion body myositis (IBM) Necrotizing myopathy (NM) What we called PM before, in some cases, is now called NM
15 Medicine, 2005
16 Classification of Myositis Adult polymyositis Adult dermatomyositis Juvenile myositis (DM >> PM) Malignancy-associated myositis Myositis in overlap with another AI disease Inclusion body myositis (IBM) Necrotizing myopathy (NM) What we called PM before, in some cases, is now called NM
17 Lundberg et al, Ann RD, 2018 For patients without classic DM rashes, do a muscle biopsy. For DM patients without muscle involvement do a skin biopsy. These criteria provide a score and probability for having IIM (for clinical trial purposes)
18 Case One 67 year old Caucasian female with HTN, hyperlipidemia, uterine cancer (1997) July, 2004: atorvastatin June, 2008: lower extremity weakness Spring, 2009: difficulty walking up steps and lifting arms overhead June, 2009: stops atorvastatin on her own but no improvement in weakness September, 2009: CK 6473, repeat 9375 Admitted to hospital; muscle biopsy: myonecrosis, no inflammation or vasculitis
19 Necrotizing Myopathy Kassardjian, JAMA Neurol, 2015
20 Case One 67 year old Caucasian female with HTN, hyperlipidemia, uterine cancer (1997) July, 2004: atorvastatin June, 2008: lower extremity weakness Spring, 2009: difficulty walking up steps and lifting arms overhead June, 2009: stops atorvastatin on her own but no improvement in weakness September, 2009: CK 6473, repeat 9375; ANA 1:320 (H) Admitted to hospital; muscle biopsy: myonecrosis, no inflammation or vasculitis Treated with prednisone (60mg/day) and CK and weakness improve
21 Case One March, 2010 (1 st UPMC visit) CK 5800 (increasing as prednisone tapered) No other autoimmune manifestations; no FH of autoimmune diseases No rashes of dermatomyositis Deltoids 4+/5; neck flexors 4/5; iliopsoas 3+/5 Statin myopathy Pt hesitant to increase prednisone
22 Immune-Mediated Necrotizing Myopathy Associated with Statins Proximal weakness during or after statin use Elevated CK Persistent weakness and elevated CK despite stopping the statin Improvement with IS agents Muscle biopsy showing necrotizing myopathy without significant inflammation Grable-Esposito, Muscle & Nerve, 2010
23 Anti-200/100 kd AutoAb Defines Subgroup of Necrotizing Myopathy (NM) 16/38 patient sera with NM had the doublet All were weak with high CK 63% had statin exposure prior to weakness 83% >age 50 exposed to statins All responded to IS therapy and many relapsed Controls in lanes 5 and 10 Christopher-Stine, Arth Rheum, 2010
24 Statin Necrotizing Myopathy HMGCR was identified as the 100-kd autoantigenic target Developed an ELISA for anti-hmgcr autoab All 16 doublet positive pts were anti-hmgcr (+) 45/750 (6%) of cohort were anti-hmgcr (+) Mammen, Arth Rheum, 2011
25 Case One April-June, 2010: worse weakness; CK 6367 July, 2010: prednisone increased (60mg/d) and mtx added Jan, 2011: added imuran/mtx (25mg/week), pred 30mg/d May, 2011: added IVIg; continued other IS agents August, 2011: clearly improved with first normal CK in July November, 2011: 5/5 strength; taper IVIg (never off completely) March, 2012: stopped imuran June, 2012: off prednisone Progressive rise of CK ; went back on mtx and IVIg; CK still elevated
26 Case One April-June, 2010: worse weakness; CK 6367 July, 2010: prednisone increased (60mg/d) and mtx added Jan, 2011: added imuran/mtx (25mg/week), pred 30mg/d May, 2011: added IVIg; continued other IS agents August, 2011: clearly improved with first normal CK in July November, 2011: 5/5 strength; taper IVIg (never off completely) March, 2012: stopped imuran June, 2012: off prednisone Progressive rise of CK ; went back on mtx and IVIg; CK still elevated Pt is anti-hmgcr autoab positive
27 Features of Anti-SRP Subset Acute onset of severe weakness with myalgias; high CK Necrotizing myopathy (or PM phenotype) no DM rash; ILD rare Poor response to therapy with variable prognosis Refractory, persistently high CK, dystrophy-like
28 Muscle Pathology of SRP Antibody Subset Necrotizing myopathy without inflammation Dimitri, Muscle and Nerve, 2007
29 Classification of Myositis Adult polymyositis Adult dermatomyositis Juvenile myositis (DM >> PM) Malignancy-associated myositis Myositis in overlap with another AI disease Inclusion body myositis (IBM) Necrotizing myopathy (NM) Anti-HMGCR Anti-SRP
30 Classification of Myositis Adult polymyositis Adult dermatomyositis Amyopathic Dermatomyositis Juvenile myositis (DM >> PM) Malignancy-associated myositis Myositis in overlap with another AI disease Inclusion body myositis (IBM) Necrotizing myopathy (NM) Anti-HMGCR Anti-SRP
31 Sometimes the skin disease can be the most dominant feature
32
33 DM Scalp Rash
34 Treatment of DM Cutaneous Disease Sun-protective measures; avoid photosensitive meds Topical GC (potency depends on severity) Topical calcineurin inhibitors (tacrolimus, pimecrolimus) Antimalarials (hydroxychloroquine or chloroquine); some dermatologists add quinacrine Oral glucocorticoids (varying doses) No Clinical Response after 1-3 months? Yes 2 nd Line Methotrexate (oral/sq) MMF 3 rd Line Taper prednisone by 20-25% monthly to minimum effective dose IVIG Tacrolimus Cyclophosphamide Rituximab
35 Apremilast in DM 50 yo woman failing GC, HCQ, aza, aza/mtx, MMF, IVIg, tacrolimus, dapsone and Acthar gel After 3 months
36 Tofacitinib in DM: Case 1 3 months 55 yo female Failed or partially responsive to GC, mtx, HCQ, aza, MMF, chloroquine, Acthar gel, tacrolimus, IVIg
37 Tofacitinib in DM: Case 2 67 yo woman with rash and arthritis Refractory to GC, mtx, HCQ, MMF, tacrolimus and Acthar gel Continued IVIg DM rash inactive (0/10) after 6 months
38 Tofacitinib in DM: Case 3 42 yo Caucasian male Rash and polyarthritis Previous mtx, MMF, HCQ, aza, intolerant to IVIg After 3 months rash and polyarthritis improved
39 Treatment of DM Cutaneous Disease Sun-protective measures; avoid photosensitive meds Topical GC (potency depends on severity) Topical calcineurin inhibitors (tacrolimus, pimecrolimus) Antimalarials (hydroxychloroquine or chloroquine); some dermatologists add quinacrine Oral glucocorticoids (varying doses) No Clinical Response after 1-3 months? Yes 2 nd Line Methotrexate (oral/sq) MMF 3 rd Line IVIG Tacrolimus Cyclophosphamide Rituximab 4 th Line Tofacitinib Apremilast Taper prednisone by 20-25% monthly to minimum effective dose
40 Myositis-specific autoantibodies Myositis specific autoantibodies X Anti-synthetase syndrome Necrotizing Clinical phenotypes in adults and children Amyopathic Dermatomyositis Fever Myositis myopathy dermatomyositis Rash Raynauds Arthropathy Lung fibrosis Mechanics hands +/- DM rash High CK Rash sine myositis Hypomyopathic Rash precedes myositis Malignancy Calcinosis/vasculitis (children) Jo-1 Anti-SRP Anti-SAE Anti-NXP-2 Zo EJ Anti-synthetases YRS PL-7 Anti-HMGCR Anti-MDA-5 Anti-TIF1g Anti-Mi-2 KS OJ PL-12 Slide courtesy of Drs. Chinoy and Gunawardena
41 Anti-CADM-140 (anti-mda-5) Amyopathic DM with rapidly progressive ILD in Japanese (Sato, Arth Rheum, 2005 and 2009) Acute/subacute interstitial pneumonitis in DM in Chinese (Chen, Rheum Int, 2011) Also described in other Asian populations with similar phenotype Target autoantigen is MDA-5. What is MDA-5? Cytoplasmic protein that senses viral RNA and induces production of type I interferon Involved in innate immune defense against viruses
42 Anti-CADM-140 (anti-mda-5) Amyopathic DM with rapidly progressive ILD in Japanese (Sato, Arth Rheum, 2005 and 2009) Acute/subacute interstitial pneumonitis in DM in Chinese (Chen, Rheum Int, 2011) Also described in other Asian populations with similar phenotype Target autoantigen is MDA-5. What is MDA-5? Cytoplasmic protein that senses viral RNA and induces production of type I interferon Involved in innate immune defense against viruses Supports role of a viral trigger
43 Anti-MDA-5 Novel cutaneous phenotype of palmar papules and cutaneous ulcerations severe vasculopathy Fiorentino, J Am Acad Derm, 2011
44 Case Two Summer, 2012: Photosensitive rash in 58 yo WF January, 2013: Polyarthritis; mild muscle weakness; rash of DM nl CK; Jo-1, ANA and SSA/B all negative improves on low dose prednisone/mtx May, 2013: DM rashes worse; faint basilar crackles on exam (no pulmonary sx); mild weakness Recommended 20mg prednisone and MMF HRCT/PFTs
45 June 6
46 Case Two July 1: Presents to local ED feeling very SOB CXR opacified In one day, she is up to 12 liters/min O 2 Contacted by rheumatologist Rash a little different
47
48 Case Two July 1: Presents to local ED feeling very SOB CXR opacified In one day, she is up to 12 liters/min O 2 Contacted by rheumatologist Rash a little different Recommend pulse steroids, cytoxan and rituximab
49 July 2
50 July 2 June 6
51 June 6 July 2 Anti- MDA-5 positive
52 Anti-MDA-5 Positivity is Associated with a Poor Pulmonary Outcome MDA5 (-) (n=106) MDA5 (+) (n=16) p<0.001 Moghadam-Kia, Arth Care Rsch, 2016
53 Myositis-specific autoantibodies Myositis specific autoantibodies Anti-synthetase syndrome Fever Myositis Raynauds Arthropathy Lung fibrosis Mechanics hands +/- DM rash X Necrotizing myopathy High CK Clinical phenotypes in adults and children X Amyopathic dermatomyositis Rash sine myositis Hypomyopathic Rash precedes myositis Dermatomyositis Rash Malignancy Calcinosis/vasculitis (children) Jo-1 Anti-SRP Anti-SAE Anti-NXP-2 Zo EJ Anti-synthetases YRS PL-7 Anti-HMGCR Anti-MDA-5 Anti-TIF1g Anti-Mi-2 KS OJ PL-12 Slide courtesy of Drs. Chinoy and Gunawardena
54 Anti-synthetase Syndrome Defines a clinically homogeneous patient population: Fever Myositis Arthritis (misdiagnosed as RA) Raynaud phenomenon Mechanic s hands ILD
55 Clinical Features: Anti-synthetase Syndrome
56 But the skin rash(es) and the myositis may be subtle and the clinical presentation may be lung dominant
57 Case Three 1/2001: 39 yo WF admitted to hospital with 5 weeks of fever ( ) and myalgias; extensive w/u negative except for low titer ANA and mild basilar fibrosis; leaves hospital with FUO frustrated by lack of diagnosis
58 Case Three 1/2001: 39 yo WF admitted with 5 weeks of fever ( ) and myalgias; extensive w/u negative except for low titer ANA and mild basilar fibrosis; leaves hospital with FUO frustrated by lack of diagnosis 3/2001 (office): worsening myalgias and arthralgias, small pleural effusions, fever, Raynaud phenomenon. Dx as UCTD and given empiric prednisone
59 Case Three 1/2001: 39 yo WF admitted with 5 weeks of fever ( ) and myalgias; extensive w/u negative except for low titer ANA and mild basilar fibrosis; leaves hospital with FUO frustrated by lack of diagnosis 3/2001 (office): worsening myalgias and arthralgias, small pleural effusions, fever, Raynaud phenomenon. Dx as UCTD and given empiric prednisone 4/2001: Increased SOB with more prominent diffuse pulmonary infiltrates; subtle Gottron changes; anti-pl-12 autoantibody identified
60 Case Three: Subsequent Course Worsening infiltrates and deteriorating PFTs PFTs: FVC 56%, FEV-1 52%, DLCO 40% Responded to glucocorticoids and tacrolimus Skin rash, joint symptoms and fever never return Never developed myositis Raynaud is mild and most recent PFTs (1/2018) FVC 75%; FEV-1 87%; DLCO 78% Echo with nl PAS (25mmHg) Currently on tacrolimus, no prednisone
61 Making the Diagnosis of Autoimmune ILD Not everyone will present with the classic anti-synthetase syndrome
62 Anti-synthetase Autoantibodies Antibody Antigen (trna synthetase) Prevalence in IIM (%) Jo-1 histidyl PL-7 threonyl <5 PL-12 alanyl <5 OJ isoleucyl <5 EJ glycyl <5 KS asparaginyl <1 Tyr tyrosyl <1 Zo phenylalanyl < 1
63 University of Pittsburgh Anti-Synthetase Cohort Autoantibody Number (% synthetases) Jo (60%) PL (16%) PL-7 27 (12%) EJ 11 (5) OJ 6 (3) KS 9 (4) Total Synthetases 229
64 University of Pittsburgh Anti-Synthetase Cohort Autoantibody Number (% synthetases) Jo (60%) PL (16%) PL-7 27 (12%) EJ 11 (5) OJ 6 (3) KS 9 (4) Total Synthetases 229
65 Initial CTD Diagnosis in Anti-Syn Cohort Jo-1 n=122 Non-Jo-1 n=80 SSc 13% PM 22% DM 24% 17% PM 59% Overlap or UCTD 48% DM 17% PM DM Overlap or UCTD SSc Aggarwal, Ann Rheum Dis, 2014
66 Initial CTD Diagnosis in Anti-Syn Cohort Jo-1 n=122 Non-Jo-1 n=80 SSc 13% PM 22% DM 24% 17% PM 59% Overlap or UCTD 48% DM 17% PM DM Overlap or UCTD SSc Myositis UCTD/Overlap Scleroderma Jo-1 83% 17% 0% Non-Jo-1 39% 48% 13% p<0.001 Aggarwal, Ann Rheum Dis, 2014
67 Survival is worse in non Jo-1 than Jo-1 patients Jo-1 non Jo-1 Aggarwal, Ann Rheum Dis, 2014
68 Survival is worse in non Jo-1 than Jo-1 patients Jo-1 non Jo-1 Diagnosis delay (years) Jo-1 non Jo-1 p value 0.4 ( ) 1.0 ( ) <0.01 Aggarwal, Ann Rheum Dis, 2014
69 Cause of Death in Anti-Synthetase Cohort Infection 6% Cancer 9% Atherosclerosis 9% Unknown 6% Pulmonary fibrosis 49% CTD kidney 3% Pulmonary HTN 11% CTD heart 5% In synthetase (+) pts pulmonary disease was most common cause of death Aggarwal, Ann Rheum Dis, 2014
70 Synthetase Positive Patients: Jo-1 vs. non-jo-1 Non Jo-1 synthetase (+) patients frequently present with non-myositis symptoms and may never manifest them. Diagnosis of a specific CTD is delayed in non-jo-1 synthetase (+) patients perhaps leading to worse survival. Synthetase (+) patients, whether Jo-1 or non Jo-1 have increased pulmonary morbidity and mortality.
71 Classification of Myositis Adult polymyositis Adult dermatomyositis Amyopathic Dermatomyositis Juvenile myositis (DM >> PM) Malignancy-associated myositis Myositis in overlap with another AI disease Inclusion body myositis (IBM) Necrotizing myopathy (NM) Anti-HMGCR Anti-SRP
72 Are there autoantibody markers that identify patients with malignancyassociated myositis?
73 Anti-p155/140 (anti-tif1-γ) Autoantibody Adults: Associated with severe cutaneous DM and cancer associated myositis JDM: Severe cutaneous involvement including ulceration, edema and calcinosis But cancer associated myositis is not seen in JDM
74 But we were seeing patients with TIF1-γ that did not have malignancy
75 Aggarwal, Rheumatology, 2014
76 Aggarwal, Rheumatology, 2014
77 Do Quantitative TIF1-γ ELISA Titers Predict Cancer Associated Myositis?
78 Anti-TIF1-γ Titers Predict Cancer 60 p = % with Cancer TIF1 negative p = TIF1 low positive (<50) TIF1 high positive ( 50) Cancer in Dermatomyositis Aggarwal et al. ACR 2012
79 Myositis-specific autoantibodies Myositis specific autoantibodies Clinical phenotypes in adults and children Anti-synthetase syndrome Necrotizing Amyopathic Dermatomyositis Fever Myositis myopathy dermatomyositis Rash Raynauds Arthropathy Lung fibrosis Mechanics hands +/- DM rash High CK Rash sine myositis Hypomyopathic Rash precedes myositis Malignancy Calcinosis/vasculitis (children) Jo-1 Anti-SRP Anti-SAE Anti-NXP-2 Zo EJ Anti-synthetases YRS PL-7 Anti-HMGCR Anti-MDA-5 Anti-TIF1g Anti-Mi-2 KS OJ PL-12 Slide courtesy of Drs. Chinoy and Gunawardena
80 Myositis Treatment: Beyond Steroids, Methotrexate and Azathioprine
81 Combination Therapy in Myositis Multiple reports of combination therapy in treatment of refractory PM and DM Literature support for combination of methotrexate and azathioprine in IIM [Villalba, Arthritis Rheum, 1998] effective in treatment-resistant myositis beneficial in those who had failed either mtx or aza alone Also consider mtx/mmf combination (anecdotal)
82 Mycophenolate Mofetil in Myositis (2-3 grams/day) 6 of 10 patients with DM successfully tapered CS with MMF [Rowin, Neurology, 2006] 3 developed opportunistic infections (other risk factors) Improvement in cutaneous features in 10/12 DM patients [Edge, Arch Derm, 2006] IVIg as add-on therapy to MMF effective in 7 severe and refractory pts (4PM/3DM) [Danielli, Autoimmunity Rev, 2009] Safe and steroid-sparing Retrospective review of 50 JDM pts using MMF for 12 months [Rouster-Stevens, Arth Care Rsch, 2010] Improved skin and muscle and steroid-sparing; well-tolerated
83 IVIg in Myositis Literature review of 308 adult patients 14 articles only 2 RCT Safe with tolerable adverse events Steroid-sparing in setting of infection Effective in esophageal involvement Acute complications or rapidly progressive disease Effective for refractory rash Might be the drug of choice in statin-associated IMNM Wang, Clin Rheumatol, 2012
84 Rituximab in Myositis Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis Chester V. Oddis, MD Ann M. Reed, MD and the RIM Study Group
85 RIM Trial Summary Primary and secondary endpoints were not achieved 83% of refractory adult and juvenile myositis patients (n=200) met the Definition of Improvement in this trial There was a significant glucocorticoid sparing between the baseline dose and the dose at study conclusion Rituximab was generally well tolerated Oddis, Arth Rheum, 2013
86 Myositis Autoantibody Subsets Predict Response to Rituximab Probability of Not Meeting DOI Primary and strongest predictors of response were Jo-1 and Mi-2 Aggarwal, A&R, 2014
87 Biologic Agents in Myositis: Selected Trials Oddis & Aggarwal, Nat. Rev. Rheumatol, 2018
88 IL-6 Blockade in Murine Model of PM IL-6 critically involved in development of myositis and muscles expressed IL-6 Treatment with tocilizumab was effective in amelioration of myositis Okiyama & Kohsaka, Arth Rheum, 2009
89 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
90 Biologic Agents in Myositis: Selected Trials Oddis & Aggarwal, Nat. Rev. Rheumatol, 2018
91 Ann Rheum Dis, 2018
92 Biologic Agents in Myositis: Selected Trials Oddis & Aggarwal, Nat. Rev. Rheumatol, 2018
93 Is Anti-T cell Therapy Rational in Myositis-associated ILD?
94 T cells as Therapeutic Targets in Myositis- Associated ILD Pathology: abundant lymphocytes and plasma cells in the lung of PM/DM pts (form lymphoid follicles)
95 T cells as Therapeutic Targets in Myositis- Associated ILD Pathology: abundant lymphocytes and plasma cells in the lung of PM/DM pts (form lymphoid follicles) Infiltrating lymphocytes in myositis NSIP pts revealed activated CD8+ T-cells [Yamadori, Rheumatol Int, 2001]
96 T cells as Therapeutic Targets in Myositis- Associated ILD Pathology: abundant lymphocytes and plasma cells in the lung of PM/DM pts (form lymphoid follicles) Infiltrating lymphocytes in myositis NSIP pts revealed activated CD8+ T-cells [Yamadori, Rheumatol Int, 2001] CD8+ and activated T-cells increased in BAL fluid of PM/DM pts (n=22) [Kurasawa, Clin Exp Immunol, 2002]
97 T cells as Therapeutic Targets in Myositis- Associated ILD Pathology: abundant lymphocytes and plasma cells in the lung of PM/DM pts (form lymphoid follicles) Infiltrating lymphocytes in myositis NSIP pts revealed activated CD8+ T-cells [Yamadori, Rheumatol Int, 2001] CD8+ and activated T-cells increased in BAL fluid of PM/DM pts (n=22) [Kurasawa, Clin Exp Immunol, 2002] Decrease in regulatory T cells in IP of CTD-ILD [Katigiri, Mod Rheumatol, 2008]
98 T cells as Therapeutic Targets in Myositis- Associated ILD Pathology: abundant lymphocytes and plasma cells in the lung of PM/DM pts (form lymphoid follicles) Infiltrating lymphocytes in myositis NSIP pts revealed activated CD8+ T-cells [Yamadori, Rheumatol Int, 2001] CD8+ and activated T-cells increased in BAL fluid of PM/DM pts (n=22) [Kurasawa, Clin Exp Immunol, 2002] Decrease in regulatory T cells in IP of CTD-ILD [Katigiri, Mod Rheumatol, 2008] Implicates activated CD8+ T-cells in myositis-associated ILD
99 Tacrolimus in Myositis and ILD Parameter p-value FVC < FEV-1 < DLCO CK < MMT 0.06 CS Dose < Retrospective study of 13 synthetase (+) pts (12 with Jo-1) Wilkes, Arth Rheum, 2005
100 Anti-T cell Therapy in Myositis-associated ILD Accumulating data on efficacy of tacrolimus/csa Wilkes, Arth Rheum, 2005 Takada, Autoimmunity, 2005 Takada, Mod Rheumatol, 2007 Guglielmo, Eur Respir J, 2009 ARDS reversed with tacrolimus Ando, Clin Rheumatol, 2010 ADM pt refractory to CsA responded to tacrolimus
101 Anti-T cell Therapy in Myositis-associated ILD Accumulating data on efficacy of tacrolimus/csa Wilkes, Arth Rheum, 2005 Takada, Autoimmunity, 2005 Takada, Mod Rheumatol, 2007 Guglielmo, Eur Respir J, 2009 ARDS reversed with tacrolimus Ando, Clin Rheumatol, 2010 ADM pt refractory to CsA responded to tacrolimus Abatacept should also be studied in AILD
102 Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease (Attack My-ILD) Proof-of-concept study: To evaluate the efficacy and safety of abatacept in myositis ILD; randomized, double blind, placebocontrolled 24-week trial followed by a 24-week open-label extension. Sponsor: Bristol Myers Squibb Principal investigator: Rohit Aggarwal Co-investigators: Chester Oddis, Siamak Moghadam-Kia
103 Long-term experience with rituximab in anti-synthetase syndrome-related ILD (Andersson et al, Rheumatology, 2015) Retrospective study
104 112 Syn+ patients 34 Tx with Rtx 30 severe ILD Long-term f/u Cohort 24/30 with 12 mth f/u 19 Jo-1; 3 PL-7; 2 PL-12 18/24 SSA (+) Acute ILD in 50% Rtx generally 2-dose regimen at days 0, 14 Median f/u from Rtx #1 = 52 mths (12-118) Mean # Rtx cycles = 2.7 (1-11) 8/24 received only 1 cycle None got monotherapy with Rtx!!
105 PFTs 24% 22% 17% % increase from baseline Andersson, Rheumatology, 2015
106 HRCT: Lung Parenchymal Involvement Pre and Post Rtx scans in 23/24 50% to 33% [p<0.001] In 5, ILD extent dropped >60% 1 increased (transplanted) Andersson, Rheumatology, 2015
107 PLOS ONE; November, 2015 J Rheum, 2016
108 Approach to treating myositis-associated ILD Oddis & Aggarwal, Nat. Rev. Rheumatol, 2018
109 Future Approaches to Guiding Therapy Take out the heterogeneity of myositis and study relevant disease subsets Better to study autoab subsets than clinical subsets Clinical/immunogenetic homogeneity Perhaps even pathologic uniformity Sequential approach using different agents Targeted biologic therapy Better exercise programs
110 University of Pittsburgh Myositis Center and Collaborators Rheumatology Rohit Aggarwal, MD, MS Siamak Moghadam-Kia, MD Many fellows over the years Pulmonary Kevin Gibson, MD Kristen Veraldi, MD, PhD Daniel Kass, MD Neuropathology David Lacomis, MD Collaborators Dana Ascherman, MD (U. Miami) Japan Masa Kuwana, MD, PhD Shinji Sato, MD Research Coordinators Diane Koontz (database manager) Many others CTD Research Laboratory Zengbiao Qi
111 Thank You
112
113 Pestronk, Curr Opin Rheum, 2011 Pathologic Myositis Classification
114 Aggarwal, Ann Rheum Dis, 2017
115 Aggarwal, Ann Rheum Dis, 2017
Myositis and Your Lungs
Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes
More informationAutoantibodies in the Idiopathic Inflammatory Myopathies
Autoantibodies in the Idiopathic Inflammatory Myopathies Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic Rochester, MN The Myositis Association Annual Conference St. Louis, MO Sept. 25,
More informationSignificance of antibody testing in idiopathic inflammatory myopathies
2/0/20 Significance of antibody testing in idiopathic inflammatory myopathies Jiří Vencovský Institute of Rheumatology, Prague Diagnosis Polymyositis Juvenile DM (JPM) Paraneoplastic Myositis in overlap
More informationAutoantibodies andprognosis. Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic
Autoantibodies andprognosis Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic HeterogeneityofIIMs Diagnosis Polymyositis Dermatomyositis IBM Necrotising myopathy Paraneoplastic Amyopathic
More informationAutoantibodies in Idiopathic Inflammatory Myopathies. Vidya Limaye Rheumatology Department Royal Adelaide Hospital
Autoantibodies in Idiopathic Inflammatory Myopathies Vidya Limaye Rheumatology Department Royal Adelaide Hospital Idiopathic Inflammatory Myopathies (IIM) Heterogeneous group of systemic autoimmune syndromes
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationMyositis 101. Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic, Rochester, MN
Myositis 101 Steven R. Ytterberg, M.D. Rheumatology Mayo Clinic, Rochester, MN Myositis Association Annual Conference Louisville, KY Sept. 6 & 7, 2018 Disclosures Consulting: Dynavax Pfizer Off-label use:
More informationOverview of Diagnostic Autoantibodies in Inflammatory Myopathy
Overview of Diagnostic Autoantibodies in Inflammatory Myopathy Minoru Satoh, M.D., Ph.D. Research Associate Professor of Medicine Division of Rheumatology and Clinical Immunology University of Florida
More informationThe many faces of myositis. Marianne de Visser Academic Medical Centre Dept of Neurology Amsterdam The Netherlands
The many faces of myositis Marianne de Visser Academic Medical Centre Dept of Neurology Amsterdam The Netherlands Outline of the presentation Classification Diagnosis Therapy Prognosis Diagnostic criteria
More informationDermatomyositis Advice from Experts: Improving Your Medical Dermatology Diagnostic and Management Skills Jeffrey P. Callen, MD Professor of Medicine
Dermatomyositis Advice from Experts: Improving Your Medical Dermatology Diagnostic and Management Skills Jeffrey P. Callen, MD Professor of Medicine (Dermatology) University of Louisville Learning Objectives
More informationDiscovery, Understanding, and Progress in Myositis
Discovery, Understanding, and Progress in Myositis Steven Ytterberg, M.D. TMA Annual Patient Conference New Orleans, LA Sept. 2, 2016 Disclosures Financial: Dynavax Corp. Pfizer Mallinckrodt American Board
More informationIDIOPATHIC INFLAMMATORY MYOPATHIES AND RELATED DISORDERS. Franclo Henning Division of Neurology Tygerberg Hospital
IDIOPATHIC INFLAMMATORY MYOPATHIES AND RELATED DISORDERS Franclo Henning Division of Neurology Tygerberg Hospital Classification systems Clinical (Bohan and Peter) Clinico-pathological (Dalakas & others)
More information4/16/2018. Demystifying weakness: how to approach refractory myositis. Objectives. Disclosures. Off-label uses for medications will be discussed
Demystifying weakness: how to approach refractory myositis Jemima Albayda, MD Assistant Professor Johns Hopkins Myositis center Disclosures Off-label uses for medications will be discussed Objectives To
More informationInflammatory Myopathies 4 th year MBBS. Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist
Inflammatory Myopathies 4 th year MBBS Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist Case A 64 woman presents with erythematous itchy rash over back of hands & forehead. For 1 month
More informationIdiopathic inflammatory muscle diseases. Dr. Paul Etau Ekwom MBChB, MMED Kenyatta National Hospital, Nairobi-Kenya
Idiopathic inflammatory muscle diseases. Dr. Paul Etau Ekwom MBChB, MMED Kenyatta National Hospital, Nairobi-Kenya I.W, 28 YRS, FEMALE SHOP STEWARD Referred to KNH on 16/06/09 from Thika Nursing Home Weakness
More informationClinical Laboratory. 14:42:00 SSA-52 (Ro52) (ENA) Antibody, IgG 1 AU/mL [0-40] Oct-18
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Rheumatoid Factor
More informationDermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan
CASE REPORT Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan Kenichiro Tokunaga 1 and Noboru Hagino 2 Abstract We performed a retrospective
More informationCase Report Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
Case Reports in Rheumatology Volume 2016, Article ID 9068061, 4 pages http://dx.doi.org/10.1155/2016/9068061 Case Report Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
More informationDisclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease
Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor
More informationThis month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma tests/panels.
February 20, 2017 Client Letter Test Update February 2017 Dear Colleague: This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma
More informationWhat are Autoantibodies and how do they work in Myositis?
What are Autoantibodies and how do they work in Myositis? Neil McHugh, University of Bath and Royal National Hospital for Rheumatic Diseases Orlando September 2015 Royal National Hospital for Rheumatic
More informationWhat your autoantibodies tell us about your disease. Mark Gourley, MD
What your autoantibodies tell us about your disease Mark Gourley, MD The Importance of the Immune System Defends us against foreign invaders Self (cancer) and Nonself (virus, bacteria, etc.) But, if the
More informationAnti-synthetase syndrome
Anti-synthetase syndrome Floranne C. Ernste, M.D. The Myositis Association Annual Conference Louisville, KY September 7, 2018 2017 MFMER slide-1 Disclosures Octapharma: clinical trial support Genentech:
More informationJUVENILE DERMATOMYOSITIS
JUVENILE DERMATOMYOSITIS - how to diagnose, how to treat? Miloš Nikolić, MD, PhD Professor and Chairman Department of Dermatology, Division of Pediatric Dermatology University of Belgrade, School of Medicine,
More informationClinical features of seven Japanese patients with anti-pl- antibody frequent positivity for anti-cyclic citrullinated peptide antibody
Cace report Clinical features of seven Japanese patients with anti-pl- antibody frequent positivity for anti-cyclic citrullinated peptide antibody Yoichiro Akiyama 1, Takao Nagashima 1, Masahiro Iwamoto
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies A Rheumatologist s Approach to Interstitial Lung Disease Outline ILD classification and patterns in CTD The clinical landscape and
More informationIdiopathic inflammatory myopathies
Myositis and cancer Idiopathic inflammatory myopathies Primary idiopathic polymyositis Primary idiopathic dermatomyositis Juvenile poly/dermatomyositis Myositis associated with another CTD Myositis associated
More informationIdiopathic inflammatory myopathies and the lung
EUROPEAN RESPIRATORY UPDATE IDIOPATHIC INFLAMMATORY MYOPATHIES Idiopathic inflammatory myopathies and the lung Jean-Christophe Lega 1,2, Quitterie Reynaud 1, Alexandre Belot 3, Nicole Fabien 4, Isabelle
More informationACR 2017 SAN DIEGO HIGHLIGHTS - INFLAMMATORY MYOPATHIES. Nikolaos Marketos Rheumatologist Volos,
ACR 2017 SAN DIEGO HIGHLIGHTS - INFLAMMATORY MYOPATHIES Nikolaos Marketos Rheumatologist Volos, 1-6-2018 No disclosures Epidemiology PM & DM Peak 5 15 yrs & 30-50 yrs : = 2-3 : 1 IBM > 50yrs : = 1 : 3
More informationThomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine. Disclosures: None
Thomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine Disclosures: None 1. idiopathic interstitial pneumonitis (IIP) - 30% of all ILD - most common form is idiopathic pulmonary fibrosis
More informationCase 1: History of J.H. Outside Evaluation. Outside Labs. Question #1
Case 1: History of J.H. 64 yo man seen at UCSF 6-256 25-07. 9 months ago onset progressive weakness of arms and legs, with muscle atrophy in arms. 4 months ago red scaly rash on face, back of hands and
More informationHUNGARIAN MYOSITIS COHORT
CLINICAL ADVANCES OF ANTI- TIF1Γ AUTOANTIBODY IN A HUNGARIAN MYOSITIS COHORT Melinda Nagy-Vincze 1, Zoltán Griger 1, Levente Bodoki 1, Zsuzsa Szankai 1, Zoe E. Betteridge 2, Katalin Dankó 1 1 University
More informationCASE REPORT. Introduction. Case Report
doi: 10.2169/internalmedicine.9553-17 http://internmed.jp CASE REPORT Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-melanoma Differentiation-associated
More informationL. Nandini Moorthy, MD MS 2012
L. Nandini Moorthy, MD MS 2012 L Nandini Moorthy, MD MS 09 17 yo Ashkenazi male with proximal muscle pain and weakness, mild malar erythema and erythema over knees and dorsal aspect of PIPs Mild tenderness
More informationIdiopathic inflammatory myopathies excluding inclusion body myositis
Idiopathic inflammatory myopathies excluding inclusion body myositis Marianne de Visser, Dept. of Neurology, Academic Medical Centre, Amsterdam, The Netherlands The idiopathic inflammatory myopathies (IIMs),
More informationThe idiopathic inflammatory myopathies
REVIEW Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations Floranne C. Ernste, MD, and Ann M. Reed, MD Abstract Recently, there
More informationClinical Laboratory. [None
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Double-Stranded DNA (dsdna) Ab IgG ELISA Detected * [None 18-289-900151 Detected] Double-Stranded DNA (dsdna) Ab IgG
More informationRheumatology E-learning. University of Szeged Department of Rheumatology and Immunology
Rheumatology E-learning University of Szeged Department of Rheumatology and Immunology Introduction Idiopathic inflammatory myopathies (IIM) are a group of systemic diseases characterized by an immune
More informationDisclosures. Integrated Approach to Treating CTD-ILD. Limitations. Relevant items to consider. Other than for SSc-ILD, no controlled data
Integrated Approach to Treating CTD-ILD Industry relationships: Disclosures Aryeh Fischer, MD Associate Professor of Medicine Division of Rheumatology Division of Pulmonary Sciences and Critical Care Medicine
More informationPOLYMYOSITIS (PM) DERMATOMYOSITIS (DM) Body myositis Eosinophilic myositis Giant cell myositis Focal / localised myositis Myopathies caused by
POLYMYOSITIS (PM) DERMATOMYOSITIS (DM) Body myositis Eosinophilic myositis Giant cell myositis Focal / localised myositis Myopathies caused by infections, drugs, toxins Definition Epidemiology Pathogenesis
More informationEvidence Review: Title. Month/ Year. Evidence Review:
Evidence Review: Title Month/ Year Evidence Review: Rituximab for connective tissue disease associated interstitial lung disease October 2014 Standard Operating Procedure: NHS England Evidence Review:
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. J. María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. J. María Pego Reigosa ABSTRACT NUMBER: 888 PHASE 3 TRIAL RESULTS WITH BLISIBIMOD, A SELECTIVE INHIBITOR OF B-CELL ACTIVATING FACTOR, IN SUBJECTS WITH MODERATE-TO-SEVERE
More information2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.
Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis
More informationAutoantibodies to a 140-kd Polypeptide, CADM-140, in Japanese Patients With Clinically Amyopathic Dermatomyositis
ARTHRITIS & RHEUMATISM Vol. 52, No. 5, May 2005, pp 1571 1576 DOI 10.1002/art.21023 2005, American College of Rheumatology Autoantibodies to a 140-kd Polypeptide, CADM-140, in Japanese Patients With Clinically
More informationUtility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting
International Journal of Clinical Rheumatology Review ositis Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting Autoantibodies directed against nuclear or cellular
More informationCorrespondence should be addressed to Yasuhiro Shimojima;
Hindawi Case Reports in Rheumatology Volume 2017, Article ID 5386797, 6 pages https://doi.org/10.1155/2017/5386797 Case Report Effective Administration of Rituximab in Anti-MDA5 Antibody Positive Dermatomyositis
More information*Pari Basharat ABSTRACT OVERVIEW OF IDIOPATHIC INFLAMMATORY MYOPATHIES
IDIOPATHIC INFLAMMATORY MYOPATHIES: ASSOCIATION WITH OVERLAP MYOSITIS AND SYNDROMES: CLASSIFICATION, CLINICAL CHARACTERISTICS, AND ASSOCIATED AUTOANTIBODIES *Pari Basharat University of Western Ontario,
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationClinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Thyroid Peroxidase (TPO) Antibody 5.0 IU/mL [0.0-9.0] 18-289-900139 16-Oct-18 Complement Component 3 50 mg/dl 18-289-900139
More informationTools to Aid in the Accurate Diagnosis of. Connective Tissue Disease
Connective Tissue Disease Tools to Aid in the Accurate Diagnosis of Connective Tissue Disease Connective Tissue Disease High quality assays and novel tests Inova offers a complete array of assay methods,
More informationBudsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital
Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases Outline What is ANA? How to detect ANA? Clinical
More informationMYOSITIS. A physician s guide to the
MYOSITIS A physician s guide to the TABLE OF CONTENTS Myositis basics... 1 contents... 3 Causes... 7... 11 Affected populations... 15 Diagnosis... 17... 25... 31 PHYSICIAN S GUIDE TO MYOSITIS matory
More informationAtlas of Antinuclear Antibodies
Fluorescence patterns of cytoplasmic autoantigens There are many important organelles in the cytoplasm which fulfill various functions of the cell as described in section 1. Various autoantibodies, known
More informationCurrent management of dermatomyositis
Dermatomyositis (DM) is a rare chronic autoimmune condition characterized by proximal muscle weakness, characteristic skin lesions and frequently, specific autoantibodies. Involvement of other organ systems,
More informationMultidisciplinary Diagnosis in Action: Challenging Case Presentations
Multidisciplinary Diagnosis in Action: Challenging Case Presentations Interstitial Lung Disease: Advances in Diagnosis and Management UCSF CME November 8, 2014 Case 1 69 yo M 3 year history of intermittent
More informationClinical Commissioning Policy Proposition:
Clinical Commissioning Policy Proposition: Rituximab for the treatment of dermatomyositis and polymyositis (Adults) Reference: NHS England A13X05/01 Information Reader Box (IRB) to be inserted on inside
More informationDiagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016
Diagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016 A/Prof Tamera Corte TSANZ Annual Conference: Perth 2016 Royal Prince Alfred Hospital, Sydney, Australia Sydney Medical School, University
More informationPrevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-mda-5) autoantibody in Brazilian patients with dermatomyositis *
Investigation 517 Particular characteristics Soares de Sá BC, of atopic Moredo eczema LF, Gomes in tropical EE, de environments. Araújo ESS, Duprat The Tropical JP Environment... 517 s Prevalence and reactivity
More informationUndifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD
Undifferentiated Connective Tissue Disease and Overlap Syndromes Mark S. Box, MD Overlap Syndromes As many as 25% of patients with rheumatic diseases with systemic symptoms cannot be definitely diagnosed
More informationClinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies
CME Review Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies Autoantibodies to various cellular constituents are detected in the sera of patients
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More informationIntravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature
Send Orders for Reprints to reprints@benthamscience.ae The Open Rheumatology Journal, 2015, 9, 77-81 77 Open Access Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review
More informationSkin Manifestations of Dermatomyositis. Victoria P. Werth, M.D. University of Pennsylvania. Chief, Dermatology Philadelphia VAMC
Skin Manifestations of Dermatomyositis Victoria P. Werth, M.D. University of Pennsylvania Chief, Dermatology Philadelphia VAMC Overview Pathogenesis: Inflammatory cells in the skin, Interferon, medications
More informationReporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation
Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Marcelo C. Pasquini, MD, MSc HVD05_1.ppt Outline Review of autoimmune diseases (AID). Role of transplantation for AID Data collection:
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationTreating dermatomyositis
Treating dermatomyositis David Fiorentino, MD, PhD Stanford University School of Medicine Department of Dermatology Department of Medicine (Rheumatology) September 25, 2010 DM affects many organs Approaching
More informationMyosites du sujet âgé
Myosites du sujet âgé Olivier Benveniste Département de Médecine Interne Centre de Référence Maladies Neuro-Musculaires Equipe Muscle Inflammatoire U974 Groupe Hospitalier Pitié-Salpêtrière Myositis classification
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. José María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. José María Pego Reigosa ABSTRACT NUMBER: 2754 Comparison of Individually Tailored vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions:
More informationSCLERODERMA SPECTRUM DISEASE
SCLERODERMA SPECTRUM DISEASE Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor King Saud University President of the Charitable Association for Rheumatic Diseases Agenda Background
More informationAcute Respiratory Distress Syndrome as the Initial Clinical Manifestation of an Antisynthetase Syndrome
CASE REPORT http://dx.doi.org/10.4046/trd.2016.79.3.188 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2016;79:188-192 Acute Respiratory Distress Syndrome as the Initial Clinical Manifestation
More informationRituximab Therapy for Myopathy Associated With Anti Signal Recognition Particle Antibodies: A Case Series
Arthritis Care & Research Vol. 62, No. 9, September 2010, pp 1328 1334 DOI 10.1002/acr.20219 2010, American College of Rheumatology ORIGINAL ARTICLE Rituximab Therapy for Myopathy Associated With Anti
More informationDisclosures. Scleroderma: Early Diagnosis How early is early? 10/28/2013. Difficult Scleroderma: How do I Approach this Patient?
Disclosures Financial support: None Difficult Scleroderma: How do I Approach this Patient? Francesco Boin, MD Assistant Professor of Medicine Director, Translational Research Johns Hopkins Scleroderma
More informationFavorable rituximab response in patients with refractory idiopathic inflammatory myopathies
de Souza et al. Advances in Rheumatology (2018) 58:31 https://doi.org/10.1186/s42358-018-0030-z Advances in Rheumatology RESEARCH Favorable rituximab response in patients with refractory idiopathic inflammatory
More informationNovel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies
Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies Analysis of 100 French Canadian Patients Yves Troyanov, MD, Ira N. Targoff, MD, Jean-Luc
More informationArthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS
Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS Introduction: There is perhaps no rheumatic disease that evokes so much fear and confusion among both patients
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Inflammatory Myositis The following talk includes discussion on offlabel usage of Campath, Rituximab, Leflunomide, and
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091593 Age 25 Years Gender Male 30/8/2017 91600AM 30/8/2017 93946AM 31/8/2017 84826AM Ref By Final COLLAGEN DISEASES ANTIBODY ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF),
More informationInterstitial Lung Disease (ILD) Diagnostic Insights Offered by CTD Serology
Interstitial Lung Disease (ILD) Diagnostic Insights Offered by CTD Serology Robert G Cooper Prof of Medicine (Muscle and Rheumatology) Normal Alveolar Physiology Contrast with ILD Pathologies Impairing
More informationPL-7 and Anti-Jo-1 Antibodies. publication is available at link.sp
NAOSITE: Nagasaki University's Ac Title Author(s) Comparison of Pulmonary Involvement PL-7 and Anti-Jo-1 Antibodies Tomonaga, Masaomi; Sakamoto, Noriho Tomoyuki; Harada, Tatsuhiko; Nakash Shintaro; Horai,
More informationRecent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationHHS Public Access Author manuscript Expert Rev Clin Immunol. Author manuscript; available in PMC 2016 May 11.
Treatment of inflammatory myopathy: emerging therapies and therapeutic targets Siamak Moghadam-Kia, Rohit Aggarwal, and Chester V Oddis * Department of Medicine, Myositis Center and Division of Rheumatology
More informationEvolving Uses of IVIG in myositis
Evolving Uses of IVIG in myositis Rossitza I. Chichkova, MD, MS Associate Professor Depts of Neurology and Internal Medicine University of South Florida, Tampa, FL Immune Function In Normal State: Protects
More informationINCREASING INCIDENCE OF IMMUNE MEDIATED NECROTIZING MYOPATHY SINGLE CENTRE EXPERIENCE
INCREASING INCIDENCE OF IMMUNE MEDIATED NECROTIZING MYOPATHY SINGLE CENTRE EXPERIENCE Martin Klein 1,2*, Heřman Mann 1,2*, Lenka Pleštilová 1,2, Josef Zámečník 3, Zoe Betteridge 4, Neil McHugh 4, Jiří
More informationArticle (Accepted version) (Refereed)
Charles Sharp, Melanie McCabe, Nick Dodds, Anthony Edey, Lloyd Mayers, Huzaifa Adamali, Ann B. Millar and Harsha Gunawardena Rituximab in autoimmune connective tissue disease associated interstitial lung
More informationTest Name Results Units Bio. Ref. Interval
135091660 Age 44 Years Gender Male 29/8/2017 120000AM 29/8/2017 100219AM 29/8/2017 105510AM Ref By Final EXTRACTABLENUCLEAR ANTIGENS (ENA), QUANTITATIVE ROFILE CENTROMERE ANTIBODY, SERUM 20-30 Weak ositive
More informationUNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS CanVasc meeting Montreal Nov 22 2012 Patrick Liang Service de rhumatologie Centre Hospitalier Universitaire
More informationClinical Differences Between Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis and Classic Dermatomyositis
CHEST Clinical Differences Between Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis and Classic Dermatomyositis Hiroshi Mukae, MD, PhD; Hiroshi Ishimoto, MD; Noriho Sakamoto,
More informationComplete Resolution of Dermatomyositis with Refractory Cutaneous Vasculitis by Intravenous Cyclophosphamide Pulse Therapy
CASE REPORT Complete Resolution of Dermatomyositis with Refractory Cutaneous Vasculitis by Intravenous Cyclophosphamide Pulse Therapy Shizuyo Tsujimura, Kazuyoshi Saito and Yoshiya Tanaka Abstract Cutaneous
More informationCitation Clinical rheumatology (2011), 30(3)
A case of antisynthetase syndrome i Titlepatient with anti-pl-12 antibody fo etanercept. Ishikawa, Yuki; Yukawa, Naoichiro; Author(s) Ohmura, Koichiro; Fujii, Takao; Usu Tsuneyo Citation Clinical rheumatology
More informationCASE REPORT. Abstract. Introduction
CASE REPORT The Clinical Characteristics of Two Anti-OJ (Anti-IsoleucyltRNA Synthetase) Autoantibody-Positive Interstitial Lung Disease Patients with Polymyositis/Dermatomyositis Kei Kunimasa 1,8, Machiko
More informationClinical characteristics of Japanese patients with anti-pl-7 (anti-threonyl-trna synthetase) autoantibodies
Clinical characteristics of Japanese patients with anti-pl-7 (anti-threonyl-trna synthetase) autoantibodies S. Sato 1, M. Hirakata 1, M. Kuwana 2, K. Nakamura 1, A. Suwa 1, S. Inada 3, T. Mimori 4, Y.
More informationANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
More informationEmerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow
Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow Lung Fibrosis/Interstitial Lung Disease Disease that affects the tissue that supports the lungs alveoli
More informationDisappearance of anti-mda-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission
RHEUMATOLOGY Rheumatology 2012;51:800 804 doi:10.1093/rheumatology/ker408 Advance Access publication 30 December 2011 Concise report Disappearance of anti-mda-5 autoantibodies in clinically amyopathic
More informationArthritis Superspeciality Center, Hubli, Karnataka and 2 Department of Rheumatology, SDM Medical College, Dharwad, Karnataka, India.
JOURNAL OF CASE REPORTS 2015;5(1):147-151 A Rare Case of Juvenile Dermatomyositis Vikram Haridas 1,2, Kiran Haridas 1 1,2 Arthritis Superspeciality Center, Hubli, Karnataka and 2 Department of Rheumatology,
More information